ATNM
Actinium Pharmaceuticals Inc
AMEX: ATNM · HEALTHCARE · BIOTECHNOLOGY
$1.39
+6.11% today
Updated 2026-09-11
Market cap
$44.02M
P/E ratio
4.00
P/S ratio
1.25x
EPS (TTM)
$0.35
Dividend yield
—
52W range
$1 – $2
Volume
0.1M
WallStSmart proprietary scores
57
out of 100
Grade: C+
Hold
Investment rating
2.7
Growth
F6.5
Quality
B7.5
Profitability
B+6.7
Valuation
B3/9
Piotroski F-Score
Weak
-12.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$3.50
+151.80%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy2 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 32.20% — above average
+ Debt/equity 0.04x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -12.17 — distress zone
- Negative free cash flow $-5.66M
- Revenue declining -100.00% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.03M | $81000.00 | $0.00 | $90000.00 | $35.09M |
| Net income | $-33.02M | $-48.82M | $-38.24M | $-33.89M | $27.90M |
| EPS | — | — | — | — | $0.35 |
| Free cash flow | $8.28M | $-47.49M | $-33.08M | $-24.68M | $-5.66M |
| Profit margin | -3,205.53% | -60,269.14% | — | -37,652.22% | 32.20% |
Peer comparison
Smart narrative
Actinium Pharmaceuticals Inc trades at $1.39. representing a P/E of 4.00x trailing earnings. Our Smart Value Score of 57/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -12.17, it sits in the distress. TTM revenue stands at $35.09M. with profit margins at 32.20%.
Frequently asked questions
What is Actinium Pharmaceuticals Inc's stock price?
Actinium Pharmaceuticals Inc (ATNM) trades at $1.39, on a P/E of 4.0x and a P/S of 1.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Actinium Pharmaceuticals Inc overvalued?
Actinium Pharmaceuticals Inc carries a Smart Value Score of 57/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Actinium Pharmaceuticals Inc (ATNM)?
The 12-month analyst consensus target is $3.50, about 151.8% above the current $1.39. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Actinium Pharmaceuticals Inc's revenue?
Actinium Pharmaceuticals Inc's trailing twelve-month revenue is $35.09M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Actinium Pharmaceuticals Inc's Altman Z-Score is -12.17, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeAMEX
CurrencyUSD
Quick metrics
P/S ratio1.25x
ROE-167.00%
Beta0.05
50D MA$0.96
200D MA$1.16
Shares out0.03B
Float0.03B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—